Dynamics of the Complement, Cytokine, and Chemokine Systems in the Regulation of Synaptic Function and Dysfunction Relevant to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common form of dementia affecting nearly 45 million people worldwide. However, the etiology of AD is still unclear. Accumulations of amyloid-β plaques and tau tangles, neuroinflammation, and synaptic and neuronal loss are the major neuropathological hallmarks of AD, with synaptic loss being the strongest correlating factor with memory and cognitive impairment in AD. Many of these pathological hallmarks influence each other during the onset and progression of the disease. Recent genetic evidence suggests the possibility of a causal link between altered immune pathways and synaptic dysfunction in AD. Emerging studies also suggest that immune system-mediated synaptic pruning could initiate early-stage pathogenesis of AD. This comprehensive review is toward understanding the crosstalk of neuron-microglia-astrocyte and dynamics of complement, cytokine, and chemokine systems in the regulation of synaptic function and dysfunction relevant to AD. We start with summarizing several immune pathways, involving complements, MHC-I and CX3CL1, which mediate synaptic elimination during development and in AD. We then will discuss the potential of targeting these molecules as therapeutic interventions or as biomarkers for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519 · cited 4×
“In the developing visual system, astrocytes secrete TGF-(cid:2) to increase neuronal C1q in order to tag weak synapses for elimination.”
InfluentialRetractedNeurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 5×
“Notably, knocking out C1q/C3 or neutralizing the C1q with a C1q-specific antibody ANX-M1 in non-transgenic mice injected with oligomeric Aβ blocked excessive pruning of synapses by microglia and prevented synaptic loss [9, 38, 40].”
InfluentialHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 1×
“Increased neuroinflammation, reflected by microglial and astroglial activation, elevated pro-inflammatory cytokine release, and early complement activation – all of these have been often observed during AD [12, 13].”
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“APOE genotype is the strongest genetic risk factor for late-onset AD, with two copies of the E4 allele leading to an increased risk by 12-fold [43], with the E2 allele being associated with 2-fold decreased risk for AD [44], and the E3 allele being the most common form and leading to intermediate risk of AD [45].”
Immune modulation of learning, memory, neural plasticity and neurogenesis
Yirmiya, R., & Goshen, I. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.015 · Cited by 1,483
Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways
Chung, W.-S., Clarke, L. E., Wang, G. X., Stafford, B. K., Sher, A., Chakraborty, C., Joung, J., Foo, L. C., Thompson, A., Chen, C., et al. (2013) · Nature · doi:10.1038/nature12776 · Cited by 1,377
Zhan, Y., Paolicelli, R. C., Sforazzini, F., Weinhard, L., Bolasco, G., Pagani, F., Vyssotski, A. L., Bifone, A., Gozzi, A., Ragozzino, D., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3641 · Cited by 1,236
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Miller, A. H., Haroon, E., Raison, C. L., & Felger, J. C. (2013) · Depression and Anxiety · doi:10.1002/da.22084 · Cited by 892
Regulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · cited 2×
“Additional studies suggested that IL-1β is the major cytokine that links both exacerbation of tau pathology (in tau models [14, 63]) and attenuation of Aβ pathology (in APP/PS1 mouse model of AD [61]).”
Self-citationMaphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Brain · doi:10.1093/brain/awv081 · Cited by 595 · cited 1×
“Recent pre-clinical and clinical research evidences suggest that neuroinflam-mation is not merely the response to pathological insults; it may even precede AD pathology and drive the pathogenesis of AD [14–16].”
Self-citationMicroglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease
Fuhrmann, M., Bittner, T., Jung, C. K. E., Burgold, S., Page, R. M., Mitteregger, G., Haass, C., LaFerla, F. M., Kretzschmar, H., & Herms, J. (2010) · Nature Neuroscience · doi:10.1038/nn.2511 · Cited by 562 · cited 1×
“On the contrary, CX3CR1 deficiency is anti-amyloidogenic in an APP/PS1 transgenic mouse model of AD [61] and fractalkine deletion can prevent neuronal loss in 5xTg mice [62].”
New insights on the role of microglia in synaptic pruning in health and disease
Hong, S., Dissing-Olesen, L., & Stevens, B. (2016) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.12.004 · Cited by 557
Lee, S., Varvel, N. H., Konerth, M. E., Xu, G., Cardona, A. E., Ransohoff, R. M., & Lamb, B. T. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100265 · Cited by 522 · cited 2×
“On the contrary, CX3CR1 deficiency is anti-amyloidogenic in an APP/PS1 transgenic mouse model of AD [61] and fractalkine deletion can prevent neuronal loss in 5xTg mice [62].”
Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study
Eikelenboom, P., & Stam, F. C. (1982) · Acta Neuropathologica · doi:10.1007/bf00685397 · Cited by 454 · cited 1×
“The amyloid-β (Aβ) plaques were shown to contain complement factors [30], and the classical complement pathway was observed to be activated in the AD patient brain [31].”
Brain microglia constitutively express β-2 integrins
Akiyama, H., & McGeer, P. L. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90055-r · Cited by 430
Kim, T., Vidal, G. S., Djurisic, M., William, C. M., Birnbaum, M. E., Garcia, K. C., Hyman, B. T., & Shatz, C. J. (2013) · Science · doi:10.1126/science.1242077 · Cited by 410 · cited 6×
“LilrB2/PirB were shown to be involved in Aβ-induced synaptic loss, decreased LTP, and increased LTD [53].”
InfluentialDo glia drive synaptic and cognitive impairment in disease?
Chung, W.-S., Welsh, C. A., Barres, B. A., & Stevens, B. (2015) · Nature Neuroscience · doi:10.1038/nn.4142 · Cited by 385
Activation of the classical complement pathway in brain tissue of Alzheimer patients
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90843-4 · Cited by 383 · cited 1×
“The amyloid-β (Aβ) plaques were shown to contain complement factors [30], and the classical complement pathway was observed to be activated in the AD patient brain [31].”
Enhanced synaptic connectivity and epilepsy in C1q knockout mice
Chu, Y., Jin, X., Parada, I., Pesic, A., Stevens, B., Barres, B., & Prince, D. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913449107 · Cited by 364 · cited 1×
“synapses in the layer V pyramidal neurons during the neocortex development [25].”
Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease
Fonseca, M. I., Zhou, J., Botto, M., & Tenner, A. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0901-04.2004 · Cited by 345 · cited 2×
“In contrast, at the pre-plaque stage (3–6 months of age), no significant changes were seen in any of the neuronal or glial markers tested [35].”
PirB restricts ocular-dominance plasticity in visual cortex
Syken, J., GrandPre, T., Kanold, P. O., & Shatz, C. J. (2006) · Science · doi:10.1126/science.1128232 · Cited by 340
Regulation of CNS synapses by neuronal MHC class I
Goddard, C. A., Butts, D. A., & Shatz, C. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702023104 · Cited by 322 · cited 1×
“It was also found to be expressed in neurons in the visual cortex, colocalized with postsynaptic proteins, and regulated by neuronal activity [48].”
Glia in mammalian development and disease
Zuchero, J. B., & Barres, B. A. (2015) · Development · doi:10.1242/dev.129304 · Cited by 304
Cho, S.-H., Sun, B., Zhou, Y., Kauppinen, T. M., Halabisky, B., Wes, P., Ransohoff, R. M., & Gan, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.254268 · Cited by 268
Genome-wide association studies in Alzheimer’s disease
Bertram, L., & Tanzi, R. E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp406 · Cited by 257
Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes
Chung, W.-S., Verghese, P. B., Chakraborty, C., Joung, J., Hyman, B. T., Ulrich, J. D., Holtzman, D. M., & Barres, B. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609896113 · Cited by 242 · cited 3×
“The amount of C1q accumulation in the hippocampus was also APOE allele-dependent in the 9- and 18-month-old APOE KI animals [42].”
InfluentialSynapse elimination and learning rules co-regulated by MHC class I H2-Db
Lee, H., Brott, B. K., Kirkby, L. A., Adelson, J. D., Cheng, S., Feller, M. B., Datwani, A., & Shatz, C. J. (2014) · Nature · doi:10.1038/nature13154 · Cited by 228
Inflammation, Antiinflammatory Agents, and Alzheimer’s Disease: The Last 22 Years
McGeer, P. L., Rogers, J., & McGeer, E. G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160488 · Cited by 215
Complement activation by neurofibrillary tangles in Alzheimer's disease
Shen, Y., Lue, L.-F., Yang, L.-B., Roher, A., Kuo, Y.-M., Strohmeyer, R., Goux, W. J., Lee, V., Johnson, G. V. W., Webster, S. D., et al. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01842-0 · Cited by 185
TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice
Jiang, T., Zhang, Y.-D., Chen, Q., Gao, Q., Zhu, X.-C., Zhou, J.-S., Shi, J.-Q., Lu, H., Tan, L., & Yu, J.-T. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.028 · Cited by 176 · cited 1×
“In a recent study, TREM2 overexpression has been shown to rescue neuronal and synaptic loss [21] and EPHA1 is thought to regulate synapse formation [22].”
Immune and Nervous Systems: More Than Just a Superficial Similarity?
Kioussis, D., & Pachnis, V. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.009 · Cited by 105
Loss of tau rescues inflammation-mediated neurodegeneration
Maphis, N., Xu, G., Kokiko-Cochran, O. N., Cardona, A. E., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00196 · Cited by 91 · cited 1×
“Additional studies suggested that IL-1β is the major cytokine that links both exacerbation of tau pathology (in tau models [14, 63]) and attenuation of Aβ pathology (in APP/PS1 mouse model of AD [61]).”
Self-citation
Cited by
Bidirectional Microglia–Neuron Communication in Health and Disease
Szepesi, Z., Manouchehrian, O., Bachiller, S., & Deierborg, T. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00323 · Cited by 459
Pomilio, C., Gorojod, R. M., Riudavets, M., Vinuesa, A., Presa, J., Gregosa, A., Bentivegna, M., Alaimo, A., Alcon, S. P., Sevlever, G., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00161-9 · Cited by 109
“Misfolded and aggregated amyloid peptides bind to pattern recognition receptors on astroglia and microglia, leading to cell reactivity and release of inflammatory mediators, which progressively contribute to the disease during chronic induction (Ahmad et al. 2019; Jiang and Bhaskar 2017).”
Maresin 1 attenuates pro‐inflammatory activation induced by β‐amyloid and stimulates its uptake
Wang, Y., Leppert, A., Tan, S., van der Gaag, B., Li, N., Schultzberg, M., & Hjorth, E. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16098 · Cited by 33
Tijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H., Reus, L. M., van der Lee, S., Wesenhagen, K. E., Lorenzini, L., Vermunt, L., Venkatraghavan, V., et al. (2023) · doi:10.1101/2023.05.10.23289793 · Cited by 10
Metadata
- Authors
- Jiang, S., & Bhaskar, K.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-03-29
- Volume
- 57
- Issue
- 4
- Pages
- 1123-1135
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2602750146
- Cited by
- 30
- References
- 38
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.